A tranched financing releases capital in stages, with later tranches conditioned on the company achieving specific clinical, regulatory, or commercial milestones - for example, IDE approval, first-patient-in, 510(k) clearance, or first commercial sale. Milestones should be objective and verifiable, with clear dates and evidence of achievement. Investors may waive a missed milestone or decline to fund the next tranche. Because later tranches are priced at the first close, achieving milestones can mean raising money at a price below the company's new value.

Why it matters

Common in MedTech where binary risk events (FDA decisions, pivotal trial readouts) make staged capital deployment attractive to investors. Founders should negotiate milestones that are objectively measurable and within the company's control.

Common pitfalls

•Accepting milestones that depend on third parties (FDA timelines, payer decisions) without clear cure provisions.

Sources

Silicon Valley Bank: tranched financings · SVB
NVCA Model Documents · NVCA
Silicon Valley Bank - Healthcare Reports · SVB
EIC Fund investment guidelines: milestone-based monitoring and investment process · European Innovation Council

Open full page

Select term B to compare.

Why compare MedTech terms side by side?

MedTech terminology is full of pairs that look interchangeable but carry very different regulatory, clinical, and commercial consequences. Picking the wrong framework, pathway, or standard early in a project can add months to a submission, invalidate clinical evidence, or trigger an audit finding. Side-by-side comparison is the fastest way to surface those differences before they become costly mistakes.

Each comparison on this page pulls from the same vendor-neutral, sourced definitions used throughout the MedTech Terms glossary. You see the one-line summary, the formal definition, why it matters in practice, common pitfalls, and the primary sources (FDA guidance, EU MDR/IVDR articles, ISO/IEC standards, MDCG documents, IMDRF principles) that back each entry. That makes the comparison defensible in regulatory strategy memos, design reviews, and submission narratives.

Common comparison patterns

Regulatory pathway choice - 510(k) vs PMA, 510(k) vs De Novo, Abbreviated vs Special 510(k).
Quality systems - QSR vs ISO 13485, QMSR vs QSR.
Software classification - SaMD vs SiMD, Locked vs adaptive AI.
EU frameworks - MDR vs IVDR, CE Mark vs UKCA.
Cybersecurity artifacts - SPDX vs CycloneDX SBOM, CVE vs CVSS.
Post-market actions - Recall vs field action, Removal vs correction.

How to use this tool

Pick term A and term B from the dropdowns, or click a preset above. The URL updates with both slugs so you can bookmark or share the exact comparison with a colleague, a notified body reviewer, or your regulatory consultant. Click Open full page on either side for the complete entry, including FAQs, related terms, and the full citation list. If you are not sure which term to start with, browse the Categories view or the A-Z index.

MedTech Terms is a vendor-neutral community resource sponsored by Blue Goat Cyber. Definitions are written for educational use and are not legal or regulatory advice.